Novo Nordisk to Present New Data on Sickle Cell and Hemophilia at ASH 2024

Novo Nordisk is gearing up to present 13 significant research abstracts at the 66th Annual Meeting and Exposition of the American Society of Haematology (ASH), scheduled for December 7-10, 2024, in San Diego. Among the highlights is the 52-week data from the phase 2 HIBISCUS trial of etavopivat, a promising investigational therapy for sickle cell disease. This data, set to be featured in an oral session on December 7, will detail the drug’s safety and efficacy, particularly its impact on reducing vaso-occlusive crises—a severe complication of sickle cell disease. The findings have been selected for the prestigious ASH Press Program, underscoring their potential significance in advancing care for this underserved patient population.

In addition to its sickle cell research, Novo Nordisk will also present updates from its haemophilia portfolio. Key oral presentations will showcase interim results from the phase 3 Frontier4 study of Mim8, a treatment designed for people living with haemophilia A, both with and without inhibitors. Another session will highlight findings from the Explorer7 trial, which evaluated concizumab in patients with haemophilia A or B who experience frequent joint bleeds. These studies aim to provide new options for managing bleeding disorders and improving patient outcomes.

Martin Holst Lange, Novo Nordisk’s Executive Vice President and Head of Development, emphasised the company’s commitment to addressing rare blood disorders. “Sickle cell disease impacts millions worldwide, yet treatment options remain limited. This year’s ASH congress marks an important milestone for us as we share data from our sickle cell research for the first time,” Lange said. “Our work builds on decades of innovation in haemophilia, and we remain dedicated to developing transformative therapies that meet the unmet needs of patients around the globe.”